上海醫藥(02607.HK)旗下血壓控制注射液通過仿制藥一致性評價

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

上海醫藥(02607.HK)旗下血壓控制注射液通過仿制藥一致性評價

阿思達克 03-05 17:20

上海醫藥(02607.HK)公布，旗下控股子公司上藥禾豐收到國家藥監局頒發的關於重酒石酸去甲腎上腺素注射液的《藥品補充申請批准通知書》，該藥品通過仿制藥質量和療效一致性評價。重酒石酸去甲腎上腺素注射液主要用於某些急性低血壓狀態的血壓控制。

上海醫藥(02607.HK)

Relevant Stocks

上海醫藥(02607.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

上海醫藥(02607.HK)旗下血壓控制注射液通過仿制藥一致性評價

Services

About Us

Agreement Statement